GRI Bio Inc. (GRI)
GRI trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2021-12-31, https://www.sec.gov/Archives/edgar/data/1824293/000182429322000004/0001824293-22-000004-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2021-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | GRI on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001824293 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2021
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$9.3M |
| Operating income | -$9.3M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | -100.0% |
| Cash | $3.7M |
| Total assets | $8.3M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "Therefore, there is substantial doubt about the Company's ability to continue as a going concern for a period of one year from the issuance of these unaudited interim consolidated financial statements." | 10-Q 2026-11-13 |
| Cash and burn | $10.9M cash; operating cash flow -$2.6M a quarter. | Report 2026-06-30 |
| Shares outstanding | 2,186,115 (2026-11-12); 3,268,727 a year earlier; 3,246,354 three years earlier. 1y figure adjusted for splits (1-for-28 overall); 3y figure adjusted for splits (1-for-43316 overall). | Cover page 2026-11-12 |
| Reverse splits, 3 years | 4; latest 1-for-28 on 2026-01-26 | Source 2026-01-26 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-01-30 |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2025-12-02 |
| Auditor | WithumSmith+Brown, PC, San Francisco, California, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-04-16 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$1.6M | -$1.4M | $10.9M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | Not filed | -$2.0M | -$3.7M | $11.0M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q4 2025 2025-12-31 | Not filed | -$2.7M | -$3.0M | $8.2M | No debt tags | Needs four quarters | 10-K 2026-01-30 |
| Q3 2025 2025-09-30 | Not filed | -$3.4M | -$2.3M | $4.1M | No debt tags | Needs four quarters | 10-Q 2025-11-14 |
| Q2 2025 2025-06-30 | Not filed | -$2.9M | -$3.2M | $5.1M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | Not filed | -$3.0M | -$1.7M | $3.3M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q4 2024 2024-12-31 | Not filed | -$1.9M | -$2.0M | $5.0M | No debt tags | Needs four quarters | 10-K 2026-01-30 |
| Q3 2024 2024-09-30 | Not filed | -$2.1M | -$2.3M | $4.7M | No debt tags | Needs four quarters | 10-Q 2025-11-14 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-01-30 |
| Latest annual report | 10-K | 2026-01-30 |
| Latest quarterly / interim | 10-Q | 2026-11-13 |
| Latest current report | 8-K | 2026-11-04 |
| Latest proxy | DEF 14A | 2026-09-28 |
Source: SEC EDGAR submissions feed, 409 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -9.6% |
| 1 month | +9.7% |
| 3 months | -4.0% |
| Year to date | -75.4% |
| 1 year | -96.4% |
| From 52-week high | -97.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| MBIO | Mustang Bio Inc. | $0.3947 | -6.34% | $3.0M |
| APUS | Apimeds Pharmaceuticals US Inc. | $2.04 | -8.52% | $3.1M |
| NRSN | NeuroSense Therapeutics Ltd. | $1.56 | -7.40% | $3.0M |
| DRMA | Dermata Therapeutics Inc. | $0.5985 | -3.65% | $3.0M |
| RDHL | Redhill Biopharma Ltd. | $0.3605 | -3.87% | $3.2M |
| MDCX | Medicus Pharma Ltd. Common Stock | $1.69 | -13.33% | $3.2M |
| ERNA | Ernexa Therapeutics Inc. | $1.69 | +0.60% | $2.9M |
| SILO | Silo Pharma Inc. | $1.57 | -14.40% | $3.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier